ConductScience.org, home

Paper6692385

Phase I study of the plant protein ricin.

Fodstad O and 6 others. Cancer Res, 1984. Cited by 69 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Phase I study of the plant protein ricin. Papers, record 6692385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6692385

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase I study of the plant protein ricin.
PubMed
Journal
Cancer Res
PubMed
Year
1984
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
2.05
iCite
Revised in PubMed
2006-11-15
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fodstad OO
2Kvalheim GG
3Godal AA
4Lotsberg JJ
5Aamdal SS
6Høst HH
7Pihl AA

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
RicinMajor topic
Abrin
Adolescent
Adult
Aged
Antibody Formation
Drug Evaluation
Female
Half-Life
Humans
Lymphoma
Male
Middle Aged

Source PubMed

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
36,140,189Ribosome-Directed Therapies in Cancer.Biomedicines2022https://conductscience.org/library/papers/36140189PubMed
34,067,057Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.Int J Mol Sci2021https://conductscience.org/library/papers/34067057PubMed
32,182,799Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties.Toxins (Basel)2020https://conductscience.org/library/papers/32182799PubMed
31,359,089Ricin and Ricinus communis in pharmacology and toxicology-from ancient use and "Papyrus Ebers" to modern perspectives and "poisonous plant of the year 2018".Naunyn Schmiedebergs Arch Pharmacol2019https://conductscience.org/library/papers/31359089PubMed
31,313,388Sensitivity of Kupffer cells and liver sinusoidal endothelial cells to ricin toxin and ricin toxin-Ab complexes.J Leukoc Biol2019https://conductscience.org/library/papers/31313388PubMed
31,216,687Intracellular Transport and Cytotoxicity of the Protein Toxin Ricin.Toxins (Basel)2019https://conductscience.org/library/papers/31216687PubMed
26,349,746Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances.Tumour Biol2015https://conductscience.org/library/papers/26349746PubMed
23,692,086Molecular mechanisms of Lycoris aurea agglutinin-induced apoptosis and G2 /M cell cycle arrest in human lung adenocarcinoma A549 cells, both in vitro and in vivo.Cell Prolif2013https://conductscience.org/library/papers/23692086PubMed
22,872,642Evaluation of riproximin binding properties reveals a novel mechanism for cellular targeting.J Biol Chem2012https://conductscience.org/library/papers/22872642PubMed
22,327,430Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.MAbs2012https://conductscience.org/library/papers/22327430PubMed
20,185,574Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.Am J Pathol2010https://conductscience.org/library/papers/20185574PubMed
12,952,291Immunotoxin therapy for CNS tumor.J Neurooncol2003https://conductscience.org/library/papers/12952291PubMed
6,488,437Pharmacological studies of ricin in mice and humans.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6488437PubMed
3,543,527Immunotoxin therapy of malignant melanoma.Med Oncol Tumor Pharmacother1986https://conductscience.org/library/papers/3543527PubMed
3,525,471Immunocytochemical detection of ricin. II. Further studies using the immunoperoxidase method.Histochem J1986https://conductscience.org/library/papers/3525471PubMed
2,188,142[100 years of lectin research--a balance].Naturwissenschaften1990https://conductscience.org/library/papers/2188142PubMed
2,074,894[Tumor lectinology--status and perspectives of clinical application].Naturwissenschaften1990https://conductscience.org/library/papers/2074894PubMed
2,039,695Lymphocyte targeted ricin as a potential therapy for lymphoid malignancy. I. Targeting efficiency.Br J Cancer1991https://conductscience.org/library/papers/2039695PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6692385

GET https://conductscience.org/api/papers/v1/6692385/authors